By Brad Sorensen, CFA
NASDAQ: ENSC
READ THE FULL ENSC RESEARCH REPORT
Ensysce Biosciences (NASDAQ: ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain relief, while greatly limiting the potential for abuse and overdoses that have plagued the American public.
Company management delivered an update that continued to center on its core strategy of developing safer opioids through its proprietary TAAP and MPAR platforms, with the earnings release emphasizing steady clinical execution rather than near-term revenue generation typical of a development-stage biotech. However, the company did report $1.9 million in grant funding for 4Q2025 and earnings loss of $0.75/share that bested analyst estimates as the company continues to keep expenses under control. Additionally, and perhaps most importantly, the company reported $4.3 million on its balance sheet—a crucial number as important testing is underway.
Operationally, management highlighted continued momentum in its lead asset, PF614, an extended-release oxycodone prodrug designed using the company’s Trypsin-Activated Abuse Protection (TAAP) technology. This approach renders the drug inactive until it is metabolized in the small intestine, which is intended to reduce abuse via tampering or non-oral routes while maintaining efficacy for severe pain. Clinical work has demonstrated bioequivalence to existing opioids with lower “drug liking” scores among recreational users, supporting its positioning as a next-generation analgesic.
The most important clinical advancement discussed is the ongoing Phase 3 program for PF614, particularly the PF614-301 study in post-surgical pain. This pivotal trial represents a key step toward potential NDA submission and commercialization, and management continues to frame it as a central value inflection point for the company, an assessment that we agree with.
Alongside PF614, Ensysce continues to advance PF614-MPAR, a combination product that incorporates its Multi-Pill Abuse Resistance (MPAR) technology. This program is designed not just to deter abuse, but to actively reduce overdose risk by limiting opioid release when excessive doses are consumed. Clinical studies to date—including multiple Phase 1 trials—have shown that the technology can “switch off” or significantly reduce oxycodone absorption in overdose scenarios, while maintaining normal therapeutic delivery at prescribed doses.
Recent updates also point to continued progress in the PF614-MPAR-102 study, which is evaluating pharmacokinetics across dosing conditions and refining the final formulation. Notably, the MPAR platform has received Breakthrough Therapy designation from the FDA, underscoring its potential clinical significance in addressing the opioid crisis by introducing overdose-protection at the drug level.
Beyond pain management, the company is also progressing an earlier-stage opioid use disorder (OUD) program, PF9001, which applies the same TAAP chemistry to methadone-like treatments with the goal of reducing both abuse potential and cardiovascular side effects. This program remains preclinical but is supported by NIH funding and represents a longer-term pipeline extension.
Overall, the earnings announcement reinforced Ensysce’s positioning as a clinical-stage company approaching a pivotal transition. While financial constraints remain a key risk, the combination of grant funding, FDA designations, and advancing clinical data continues to support the company’s strategic trajectory, and we urge investors to take a look at ENSC at this inflection point.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.